<DOC>
	<DOCNO>NCT02870036</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , preliminary efficacy pharmacokinetics Simmitecan patient advance solid tumor Simmitecan , 5-fluorouracil Leucovorin Calcium patient advance solid tumor advanced/metastatic colorectal cancer .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Preliminary Efficacy Pharmacokinetics Simmitecan Simmitecan , 5-fluorouracil Leucovorin Calcium , Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>1 . To enrol study , patient shall meet follow criterion : Patients fully understood study , willing sign inform consent form ( ICF ) ; 2 . To enrol part 1 , 2 3 study , patient diagnose advanced solid tumor pathological histology and/or cytology ; patient diagnose advanced metastatic CRC pathological histology prior enrollment part 4 study ; Note : patient enrol part 2 study shall patient advance solid tumor suitable regimen Simmitecan combine 5FULV judged investigator ; 3 . Patients fail standard treatment advanced cancer , intolerant current standard treatment , suitable standard treatment advanced cancer ; 4 . Patients least one measurable lesion ( accord RECIST , version 1.1 ) ; note : lesion previously treat radiotherapy regard target lesion , unless lesion show definite progression radiotherapy ; 5 . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 ; 6 . Patients age ≥ 18 year ≤ 70 year , male female allow ; 7 . Patients life expectancy 12 week ; 8 . Patients appropriate organ function document : 1 . Absolute neutrophil count ≥ 1.5×109/L ; 2 . Hemoglobin ≥ 9 g/dL ( without erythrocyte transfusion within 14 day ) ; 3 . Platelet count ≥ 100×109/L . 4 . Total serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) ( patient Gilbert syndrome , total bilirubin allow ≤ 3×ULN direct bilirubin allow 1.5×ULN ) ; 5 . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) ≤ 2.5×ULN , AST ALT ≤ 5×ULN patient liver metastasis ; 6 . Creatinine clearance ≥ 50 mL/min ; 7. International normalize ratio ( INR ) ≤ 1.5 × ULN , activate partial thromboplastin time ( aPTT ) ≤ 1.5 × ULN ( INR patient receive anticoagulant therapy ) . 9 . Patients negative hepatitis b surface antigen ; patient positive hepatitis b surface antigen , quantitative result hepatitis b virus ( HBV ) DNA &lt; 1000 cps/mL ; 10 . Toxicity cause previous treatment , surgery radiotherapy recover CTCAE grade 0 1 ( except alopecia ) ; 11 . Female patient eligible study follow condition meet : 1 . Patients fertility ( i.e. , physiological infertility ) , include postmenopausal period ( complete menolipsis 1 year ) document irreversible sterilization operation include hysterectomy , bilateral ovariectomy , bilateral salpingectomy ( instead tubal ligation ) ; 2 . For patient childbearing potential , result serum pregnancy test screen negative ( within 7 day first dose investigational drug ) , breastfeed allow start study throughout study . Moreover , patient agree take effective contraception measure study within 90 day last dose , always conduct strict birth control accordance label drug/appliance investigator 's instruction . Effective contraception measure define : The sexual partner remove deferens sexual partner female patient ; Use intrauterine device document failure rate le 1 % per year ; Double contraception , spermicide plus male condom , female condom , diaphragm , cervical cap intrauterine contraceptive device . 12 . Male patient undergone vasectomy , agree take effective contraception measure study within 90 day last dose ; 13 . Patients able follow study procedure , restriction requirement investigator 's discretion . 1 . Patients still within 5 halflife previous anticancer chemotherapy , biological agent investigational drug ( 5 halflife exceeds 28 day calculate 28 day ) time screen ; 2 . Patients receive systemic radiotherapy ( include whole brain radiotherapy ) within 28 day enrollment , receive small area radiotherapy ( stereotactic radiotherapy central nervous system ( CNS ) ) within 7 day enrollment , yet recover previous radiotherapy ; 3 . Patients yet recover toxic reaction ( except alopecia ) cause previous antitumor treatment ( &gt; CTCAE grade 2 ) ; 4 . Patients underwent major surgery yet fully recover pervious surgery ( major surgery define grade 3 4 surgery specify `` Management Measures Clinical Application Medical Technology '' implement May 1st , 2009 ) . 5 . Patients CNS metastasis cancerrelated epilepsy require clinical intervention ; however , patient CNS metastasis receive treatment , asymptomatic patient enrol ; 6 . Patients history allergy 5FU LV ; 7 . Patients active HBV hepatitis C virus ( HCV ) infection ; 8 . Patients diagnose human immunodeficiency virus ( HIV ) infection , willing HIV test ; 9 . Patients clinically significant active infection ; 10 . Patients previous concurrent malignant tumor ( except effectively control nonmelanoma skin basal cell carcinoma , breast/cervical carcinoma situ , effectively control tumor past 5 year even without treatment ) ; 11 . Patients impaired cardiac function clinically significant heart disease , include grade 2 high congestive heart failure per New York Heart Association ( NYHA ) classification , arrhythmia , conduction abnormality require treatment , cardiomyopathy , uncontrolled hypertension ; 12 . Patients serious kidney damage require kidney dialysis ; 13 . Patients serious liver damage , grade B C endstage liver diseases per ChildPugh classification ( see appendix 8 ) ; 14 . Any disease condition clinical significance may affect protocol compliance patient 's signature ICF investigator 's discretion ( uncontrolled diabetes , etc . ) ; 15 . Patients disease digestive tract duodenal ulcer , ulcerative colitis , intestinal obstruction condition may cause alimentary tract hemorrhage gastrointestinal perforation judge investigator , past medical history gastricintestinal perforation intestinal fistula ; 16 . Patients physical condition cause risk investigational drug use , render toxicity adverse effect difficult explain investigator 's discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>